| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.1 | -1.0 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: OTLC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Oncotelic Therapeutics, Inc.: key numbers
- Share price
- $0.0134Close, Nov 16
- Market cap
- $6.13M
- Shares outstanding
- 457.51MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oncotelic Therapeutics, Inc.
All →Oncotelic Therapeutics Chairman and CEO Vuong Trieu Buys $17.8K of Stock
Vuong Trieu, Chairman and CEO, bought 1,044,990 shares of Oncotelic Therapeutics, Inc. at $0.017 a share, worth $17.8K in total on Oct 29, 2026. Shares held after the trade: 95,481,309 (+1.1%).
- Value
- $17.8K
- Shares
- 1,044,990
- Price
- $0.0170
- Role
- Chairman and CEO
- Holding change
- +1.1%
- Trade date
- Oct 29, 2026
Oncotelic Therapeutics Investor Presentation
Oncotelic Therapeutics presented its Partitioned Literature Aggregation (PLA) framework at the 22nd Drug Discovery Strategic Summit. The presentation detailed the use of AI and literature analysis to identify a four-gene mTOR signature for hepatocellular carcinoma and outlined plans for an AI-driven research environment targeting 100 billion protein-related vectors.
Oncotelic Therapeutics Investor Presentation
Oncotelic Therapeutics presented details on its PDAOAI platform and hepatocellular carcinoma (HCC) research at the Drug Discovery 2026 conference. The presentations highlighted a four-gene mTOR-related signature associated with patient survival and introduced the 'BIO REBOOT' initiative to support new therapeutic research projects.
- Counterparty
- Drug Discovery 2026